Lumosa
順天醫藥生技股份有限公司
Lumosa is a Taiwan TPEx-listed biotechnology company; its most advanced asset is LT1001 (Commercialized, Postoperative pain), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| LT1001 | — | Commercialized | Postoperative pain | Taiwan, Singapore, Thailand, Malaysia, Ukraine | — | Company disclosure |
| LT3001 | — | Phase 2 exploratory trial authorized | Acute ischemic stroke | Taiwan | 2026-05-26 | Company disclosure |
| LT6001 | — | IIT / compassionate use; phase unspecified | Neurological diseases | — | — | Company disclosure |
Key events
- Business update (company filing)